Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Martin L Williams, Deborah Rudin, Yasmin Schmid, Jacqueline L von Salm
Frontiers in Psychiatry April 23, 2025 DOI: 10.3389/fpsyt.2025.1600812 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychedelic medicine Mental health treatments Alternative therapy Drug research Therapeutic compounds |
Abstract
However, psilocybin is but one of scores of compounds belonging to two main chemical classesphenethylamines and tryptamines -along with ergolines and an expanding array of other (mostly heterocyclic) alkaloids -that act as agonists of the serotonin 5-HT2A, 5-HT2C and 5-HT1A receptors responsible for the various phenomenological and putative therapeutic effects of classic psychedelics (8). In addition, attention is turning to other compounds within the broader class now known as "psychoplastogens", that do not elicit the characteristic phenomenological effects associated with psychedelics but nonetheless show promise as pharmacotherapeutic agents through promotion of neuroplasticity (9).
Citations in the library
Cites 8
- The neural basis of psychedelic action. Nature Neuroscience October 24, 2022
- Psilocybin desynchronizes the human brain. Nature August 1, 2024
- Psychedelics and Other Psychoplastogens for Treating Mental Illness Frontiers in Psychiatry October 4, 2021
- Psychedelics and Psychotherapy. Pharmacopsychiatry July 1, 2021
- The Emerging Field of Psychedelic Psychotherapy. Current Psychiatry Reports October 1, 2022
and 3 more in the library